Camille Berquin

Dr. Camille Berquin

orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2022 in Urologic Oncology: Seminars and Original Investigations
Verified
Journal Article
Closed access
GRGiuseppe Rosiello
Giuseppe Rosiello
PPPietro Piazza
Pietro Piazza
SPStefano Puliatti
Stefano Puliatti
EMElio Mazzone
Elio Mazzone
MAMarco Amato
Marco Amato
AMAlexandre Mottrie
Alexandre Mottrie

20 July 2023 in Urologic Oncology: Seminars and Original Investigations
Verified
Journal Article
Closed access
CBCamille Berquin
Camille Berquin
GPGianpaolo Perletti
Gianpaolo Perletti
DDDries Develtere
Dries Develtere
HPHannah Van Puyvelde
Hannah Van Puyvelde
EPElisabeth Pauwels
Elisabeth Pauwels
GNGeert De Naeyer
Geert De Naeyer

17 March 2023 in Current Oncology
Verified
Journal Article
Open access
PDF file
ELEdward Lambert
Edward Lambert
CACharlotte Allaeys
Charlotte Allaeys
CBCamille Berquin
Camille Berquin
Pieter Julien Luc De VisscherePieter Julien Luc De Visschere
Pieter Julien Luc De Visschere
SVSofie Verbeke
Sofie Verbeke
NLNicolaas C. Lumen
Nicolaas C. Lumen
Background: Retzius-sparing robot-assisted radical prostatectomy (RS-RARP) has been shown to lead to better outcomes regarding early continence compared to standard anterior RARP (SA-RARP). The goal of this study was to assess the feasibility and safety of implementing RS-RARP in a tertiary center with experience in SA-RARP. Methods: From February 2020, all newly diagnosed non-metastatic prostate cancer patients for whom RARP was indicated were evaluated for RS-RARP. Data from the first 100 RS-RARP patients were prospectively collected and compared with data from the last 100 SA-RARP patients. Patients were evaluated for Clavien Dindo grade ≥3a complications, urinary continence after 2 and 6 weeks, 3, 6 and 12 months, erectile function, positive surgical margins (PSMs) and biochemical recurrence (BCR). Results: There was no significant difference in postoperative complications at Clavien-Dindo grade ≥3a (SA-RARP: 6, RS-RARP: 4; p = 0.292). At all time points, significantly higher proportions of RS-RARP patients were continent (p < 0.001). No significant differences in postoperative potency were observed (52% vs. 59%, respectively, p = 0.608). PSMs were more frequent in the RS-RARP group (43% vs. 29%, p = 0.034), especially in locally advanced tumors (pT3: 64.6% vs. 43.8%, p = 0.041—pT2: 23.5% vs. 15.4%, p = 0.329). The one-year BCR-free survival was 82.6% vs. 81.6% in the SA-RARP and RS-RARP groups, respectively (p = 0.567). The median follow-up was 22 [18–27] vs. 24.5 [17–35] months in the RS-RARP and SA-RARP groups, respectively (p = 0.008). Conclusions: The transition from SA-RARP to RS-RARP can be safely performed by surgeons proficient in SA-RARP. Continence results after RS-RARP were significantly better at any time point. A higher proportion of PSMs was observed, although it did not result in a worse BCR-free survival.

30 April 2022 in Journal of Surgical Research
Verified
Journal Article
Closed access
SPStefano Puliatti
Stefano Puliatti
MAMarco Amato
Marco Amato
EMElio Mazzone
Elio Mazzone
GRGiuseppe Rosiello
Giuseppe Rosiello
RGRuben De Groote
Ruben De Groote
AGAnthony G. Gallagher
Anthony G. Gallagher

18 April 2023 in Journal of Pediatric Urology
Verified
Journal Article
Closed access
JJJolien Van Der Jeugt
Jolien Van Der Jeugt
CJCaroline Jamaer
Caroline Jamaer
CBCamille Berquin
Camille Berquin
KDKarel Decaestecker
Karel Decaestecker
PHPiet Hoebeke
Piet Hoebeke
ASAnne-Francoise Spinoit
Anne-Francoise Spinoit

1 October 2022 in Journal of Pediatric Urology
Verified
Journal Article
Closed access
CBCamille Berquin
Camille Berquin
CJC. Jamaer
C. Jamaer
LML. Van Moerkerke
L. Van Moerkerke
EVE. Vandamme
E. Vandamme
MWM. Waterschoot
M. Waterschoot
ASA.F. Spinoit
A.F. Spinoit